Mark A. Smith

Mark A. Smith is an experienced professional in the field of healthcare and pharmaceuticals. Mark A. began their career as a Discovery Project Leader at DuPont Merck Pharma in 1996 and then transitioned to AstraZeneca, where they served as a Medical Science Director for 12 years. Following this, Mark held positions as Senior Director of Experimental Medicine at Shire Pharmaceuticals and Senior Director and Lead for Neurology/Psychiatry at Teva Specialty Pharmaceuticals. In 2016, they joined VistaGen Therapeutics, Inc. as the Chief Medical Officer, a role they held until 2022. Currently, Mark is working as an Independent Consultant and has recently taken on the role of Chief Medical Officer at Bright Minds Biosciences. With a diverse and extensive background in the pharmaceutical industry, Mark brings a wealth of expertise to their current roles.

Mark A. Smith completed a Psychiatry Residency at Duke University School of Medicine from 1984 to 1987. Prior to that, they pursued a Doctor of Medicine (MD) and a PhD at UC San Diego from 1977 to 1984. In 1977, they obtained a Bachelor of Science (B.S.) degree from Yale University. The field of study for their degrees is not specified.